Silvia Pastorekova

This inventor holds 36 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Cancer Diagnostics. Top assignees: Institute of Virology Slovak Academy of Sciences, Institute of Virology of the Slovak Academy of Sciences, Institute of Virology of the Slovak Academy of Science. Active years: 1999-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Silvia Pastorekova. Retrieved from https://idiyas.com/inventor/silvia-pastorekova

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 (Patent Applications = 4)

% Patents Active = 38.9

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 3.4

ph-index = 9

Forward Citations = 245(Granted Patents)

Location History:

Bratislava, CZ (2001)
Stupava, SK (2009 - 2011)
Bratislava, SK (1999 - 2014)

Company Filing History:

18 out of 20

Institute of Virology Slovak Academy of Sciences

patents

14 out of 18

Institute of Virology of the Slovak Academy of Sciences

patents

2 out of 2

Institute of Virology of the Slovak Academy of Science

Institute of Virology, Solvak Academy of Sciences

patent

Years Active: 1999-2014

Loading Chart...

Areas of Expertise:

Viral Diagnostics

MN Gene

Protein Inhibitors

Cancer Prognosis

Carbonic Anhydrase IX

Monoclonal Antibodies

Tumor Growth Inhibition

Antibody Detection

Immunological Methods

Hybridomas

Cancer Treatment

Polypeptides

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8883429 - Viral diagnostics (2014-11-11),

2. 8759493 - MN gene and protein (2014-06-24),

3. 8628771 - CA IX-specific inhibitors (2014-01-14),

4. 8025865 - CA IX-specific inhibitors (2011-09-27),

5. 8012707 - MN gene and protein (2011-09-06),

6. 7993852 - MN/CA IX and cancer prognosis (2011-08-09),

7. 7910691 - MN gene and protein (2011-03-22),

8. 7846673 - Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX'S coexpression with HER-2/neu/c-erbB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes (2010-12-07),

9. 7833739 - CA IX-specific inhibitors (2010-11-16),

10. 7833738 - CA IX-specific inhibitors (2010-11-16),

11. 7833737 - CA IX-specific inhibitors (2010-11-16),

12. 7833734 - CA IX-specific inhibitors (2010-11-16),

13. 7833728 - Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX's coexpression with HER-2/neu/c-erbB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes (2010-11-16),

14. 7833514 - CA IX-specific inhibitors (2010-11-16),

15. 7829065 - CA IX-specific inhibitors (2010-11-09),

Title: Silvia Pastorekova: Innovative Contributions in Viral Diagnostics and Cancer Research

Introduction:

Silvia Pastorekova, a prominent inventor and researcher based in Bratislava, Slovakia, has made significant contributions in the fields of viral diagnostics and cancer research. With an impressive number of 36 patents to her name, Silvia Pastorekova has been instrumental in developing methods and technologies that have improved the detection and treatment of diseases.

Latest Patents:

Silvia Pastorekova's recent patents highlight her expertise in viral diagnostics and cancer-related research. One of her notable patents involves methods for determining whether a subject is infected with the lymphocytic choriomeningitis virus (LCMV). By utilizing specific compositions for detecting LCMV, this innovation enables the identification of infected individuals, facilitating faster diagnosis and containment of the virus.

Another important patent by Pastorekova revolves around the MN gene and its associated proteins. The invention provides insights into the relationship between the expression of the MN gene and tumorigenicity. This breakthrough discovery paves the way for diagnostic and prognostic methods to detect and quantify MN antigen and antibodies, aiding the diagnosis and prognosis of neoplastic and pre-neoplastic diseases.

Career Highlights:

Silvia Pastorekova has worked in esteemed institutions, including the Institute of Virology Slovak Academy of Sciences and the Institute of Virology of the Slovak Academy of Sciences. In her extensive career, she has focused on understanding and combating viral infections and their impact on human health. Pastorekova's expertise in the field has earned her numerous accolades and recognition for her groundbreaking research and inventions.

Collaborations:

Throughout her career, Silvia Pastorekova has collaborated with accomplished scientists and researchers. Notably, she has worked closely with Jaromir Pastorek and Jan Zavada, who have substantially contributed to her research projects. Their collaborative efforts have synergistically enhanced the outcomes of their endeavors, leading to innovative solutions in viral diagnostics and cancer research.

Conclusion:

Silvia Pastorekova's contributions to the fields of viral diagnostics and cancer research have significantly advanced the understanding and treatment of various diseases. Her latest patents demonstrate her profound knowledge in detecting the lymphocytic choriomeningitis virus and harnessing the potential of the MN gene and associated proteins in diagnosing neoplastic and pre-neoplastic conditions. With her unwavering commitment to innovation and scientific excellence, Silvia Pastorekova continues to make lasting contributions to the field of medical research and patents.

Profile summary based on public USPTO records.